Pharmaceutical Technology, Jan 2, 2009 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Jan 2, 2009
Online Exclusive
It's Only Natural: Using Polymers in Drug Delivery
By Heidi M. Mansour
A book explains the many pharmaceutical applications of polymers from natural sources.
Silicone Microdroplets in Protein Formulations—Detection and Enumeration
By Deepak K. Sharma , Peter Oma , Sampath Krishnan
The authors describe a novel analytical approach that uses the shape-analysis capabilities of MFI to detect and enumerate silicone oil microdroplets in protein formulations that also contain aggregates of similar size and in a similar concentration.
Special Report
Evaluating the Pieces of the Pharma Supply Chain
By Angie Drakulich , Patricia Van Arnum
After a year of increased attention on the pharmaceutical supply chain in Asia, what will be the region's short- and long-term role? This article contains bonus online-exclusive material.
Peer-Reviewed Research
Integration of Large-Scale Chromatography with Nanofiltration
By Aline Denton , Carl Jones , Klaus Tarrach
The authors examine the challenges of integrating a large-scale chromatography and nanofiltration process for purification of a polyclonal antibody.
The Case of Blister-Filling and Packaging Systems
By Toyohiko Takeda , Hiroshi Hirasawa
The authors propose an approach for qualification-target selection and show how it can be applied to blister-filling and packaging systems.
The Postapproval Management Plan
By Paula S. Hudson , Denyse D. Baker
The authors propose that a postapproval management plan can serve as a tool to apply science- and risk-based approaches to the manufacturing process.
Ingredients Insider
Optimizing Small-Molecule Synthesis
By Patricia Van Arnum
Catalysis for olefin metathesis and aldol reactions and synthetic routes to natural products are some recent gains.
Outsourcing Outlook
Survival of the Fittest Companies
By Jim Miller
The financial crisis could lead to consolidation in the contract services industry.
Washington Report
FDA at a Crossroads
By Jill Wechsler
Will more resources and new leadership fix FDA, or is a major overhaul in order?
Insider Solutions
Insider Solutions: Have a Say in USP Standards
By Susan J. Schniepp
The USP public-comment process exists for a reason. Industry needs to take advantage. This article contains bonus online-exclusive material.
Agent-In-Place
An Ounce of Rejection
By Control, a senior compliance officer
Readers give advice on their best approach to handling (batch) rejection
From The Editor
A New Start for New Cells
By Michelle Hoffman
The incoming administration has renewed hope for stem cells, but less adequate copycats may follow.
Viewpoint
Selecting the Next FDA Commissioner—A PhRMA Perspective
By Alan Goldhammer
President Obama's choice for agency leadership should take into account several factors.
News
Report from: Pakistan
By Jane Wan
Although its domestic market is on the rise, Pakistan's market conditions have not proved welcoming enough to keep foreign investors.
PharmTech Talk
Will 2009 Bring Innovation?
By Erik Greb
Instead of hampering progress, cost pressures might inspire Big Pharma to get creative.
In the Spotlight
In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations
Pharma Capsules
Pharma Capsules
Brief pharmaceutical news items for January 2009.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here